相关临床试验
557
49 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
34
6.1%
已完成
385
69.1%
Enrolling By Invitation
1
0.2%
尚未招募
14
2.5%
招募中
41
7.4%
暂停
2
0.4%
终止
58
10.4%
Unknown
2
0.4%
撤回
20
3.6%
暂无批准数据
- The global wearable cardiac monitoring devices market was valued at USD 2.9 billion in 2025 and is projected to reach USD 10.3 billion by 2036, expanding at a CAGR of 12.1%. - The electrocardiography (ECG) technology segment dominated the market in 2025, accounting for approximately 62.1% of total revenue, driven by its clinical accuracy in detecting arrhythmias and atrial fibrillation. - North America held the largest regional share at 41.2% in 2025, supported by advanced healthcare infrastructure and growing adoption of remote patient monitoring solutions. - Rising prevalence of cardiovascular diseases and cardiac arrhythmias, coupled with growing demand for continuous, real-time cardiac monitoring, is the primary growth driver.
- Boston Scientific's FRACTURE IDE trial demonstrated that the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter achieved 93.3% freedom from major adverse cardiac events at 30 days, exceeding the prespecified performance goal. - The device showed 93.7% procedural success rate and achieved 100% successful stent delivery in 420 patients with severely calcified coronary artery disease. - The trial results support regulatory submission for the investigational device, which uses laser energy to generate acoustic pressure waves that fracture calcium deposits in coronary arteries. - Moderate-to-severe coronary calcification affects nearly one-third of patients undergoing percutaneous coronary intervention, presenting significant procedural challenges and complication risks.
- Boston Scientific invested $1.5 billion for a 34% equity stake in MiRus LLC, securing exclusive option rights to acquire the company's innovative SIEGEL balloon-expandable TAVR system. - The SIEGEL valve represents the first nickel-free, balloon-expandable TAVR device built with proprietary rhenium alloy, offering superior radial strength and precise delivery through a 50% smaller sheath. - MiRus has initiated the STAR pivotal trial evaluating the SIEGEL valve in up to 1,025 patients with severe aortic stenosis across all surgical risk categories. - The acquisition option could reach $3 billion in additional payments upon achieving clinical and regulatory milestones, potentially expanding Boston Scientific's structural heart portfolio.
- Boston Scientific Corporation received FDA 510(k) clearance for the Asurys Fluid Management System, designed to provide automated irrigation management during endoscopic urologic procedures including ureteroscopy for kidney stone treatment. - The system addresses a critical clinical challenge by automatically regulating irrigation inflow to help minimize intrarenal pressure, which can contribute to serious post-operative complications including sepsis and renal damage. - When paired with the LithoVue Elite Single-Use Digital Flexible Ureteroscope, the Asurys System enables real-time intrarenal pressure monitoring and automated response, representing the first system capable of automatically responding to pressure data during procedures. - The device can be used across multiple urologic procedures including ureteroscopy, cystoscopy, percutaneous nephrolithotomy, and benign prostatic hyperplasia procedures, with limited market release beginning immediately.
- Researchers at London Health Sciences Centre Research Institute have launched a Phase II clinical trial using TheraSphere™ Glass Microspheres to deliver internal radiation therapy directly to kidney cancer tumors. - The innovative approach targets renal cell carcinoma patients who are not surgical candidates due to advanced age or comorbid conditions, addressing a critical unmet medical need. - The microscopic glass beads containing Yttrium-90 can deliver up to 10 times more radiation than external therapy while preserving healthy kidney tissue. - The trial will enroll up to 16 patients with localized kidney cancer at the Verspeeten Family Cancer Centre, with funding provided by Boston Scientific Corporation.
- Elutia Inc. has entered into a definitive agreement to sell its EluPro™ and CanGaroo® bioenvelopes to Boston Scientific Corporation for $88 million in cash, with the deal expected to close in Q4 2025. - The transaction validates Elutia's proprietary drug-eluting biologics platform and provides non-dilutive funding to advance its NXT-41 and NXT-41x pipeline targeting the $1.5 billion breast reconstruction market. - EluPro has demonstrated commercial success with seven national group purchasing organization contracts and more than 160 value analysis committee approvals since its launch. - The acquisition enables Elutia to eliminate outstanding debt, resolve litigation from its divested Orthobiologics business, and focus resources on its SimpliDerm franchise and breast reconstruction technologies.
- DelveInsight's 2025 pipeline assessment reveals three key companies are developing novel hemorrhoids treatment therapies, with emerging drugs like EB02, Halo-Lido, and Hydrocortisone Acetate Suppository expected to significantly impact the market. - Citius Pharmaceuticals completed a Phase 2b trial for Halo-Lido (CITI-002) in 2023 and applied for patents in June 2023, positioning the topical formulation as a promising treatment for hemorrhoid relief. - The hemorrhoids treatment market faces growth drivers including rising awareness and increased reported cases, while barriers include lack of specialized healthcare infrastructure and time-consuming treatment procedures.
- The Society of Interventional Oncology's ACCLAIM Trial successfully enrolled 330 tumors in 240 patients with colorectal liver metastases eight months ahead of the enrollment deadline. - This landmark study represents the first global, prospective trial to incorporate objective ablation margin confirmation as a technical endpoint in interventional oncology. - The multi-million-dollar trial involves nine leading cancer centers across the United States and Europe, with funding from Boston Scientific, NeuWave Medical, and Varian. - The primary endpoint aims to determine whether complete margin coverage during microwave ablation correlates with 24-month local tumor progression-free survival.
- The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients. - DETOUR2 study reveals the durability of percutaneous transmural arterial bypass with the DETOUR System for complex femoropopliteal disease, showing promising 3-year outcomes. - SIRONA trial's post-hoc analysis suggests sirolimus-coated balloons as a viable alternative to paclitaxel-coated balloons in femoropopliteal angioplasty. - ELEGANCE registry indicates that drug-eluting devices in endovascular PAD treatment yield excellent 1-year outcomes in underrepresented patient groups.
- The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients. - DETOUR2 study shows percutaneous transmural arterial bypass with the DETOUR System offers durable outcomes for complex femoropopliteal lesions at three years. - The LIFE-BTK trial indicates the Global Limb Anatomic Staging System (GLASS) effectively identifies CLTI patients at higher risk for adverse events.
